Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | MTOR | P42345 | 2/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
| ▸ | ATR | Q13535 | 2/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.43 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26113241 | 1.00 | GPR119 (0.53) | GPR119NR3C1CYP3A4CYP2C9PIK3CA | |
| SCHEMBL26115719 | 0.83 | KDM5A (0.41) | GPR119 | |
| SCHEMBL31467864 | 0.83 | GPR119 (0.52) | GPR119NR3C1CYP3A4CYP2C9PIK3CA | |
| SCHEMBL514912 | 0.83 | GPR119 (0.52) | GPR119NR3C1CYP3A4CYP2C9PIK3CA | |
| SCHEMBL15325963 | 0.81 | GPR119 (0.55) | GPR119NR3C1CYP3A4CYP2C9PIK3CA | |
| SCHEMBL27459420 | 0.80 | GPR119 (0.50) | GPR119NR3C1CYP3A4CYP2C9PIK3CA | |
| SCHEMBL30588468 | 0.80 | GPR119 (0.51) | GPR119NR3C1CYP3A4CYP2C9PIK3CA | |
| SCHEMBL26119864 | 0.80 | GPR119 (0.51) | GPR119NR3C1CYP3A4CYP2C9PIK3CA | |
| SCHEMBL31602669 | 0.79 | GPR119 (0.58) | GPR119NR3C1CYP3A4CYP2C9PIK3CA | |
| SCHEMBL29507014 | 0.79 | GPR119 (0.68) | GPR119NR3C1CYP3A4CYP2C9PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577231-B2 | Androgen receptor PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-06-26 | — | — | US | disclosed |
| WO-2025061906-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-27 | — | — | WO | disclosed |
| EP-4499628-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023180388-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | AR, CRBN, PSMA3 | GPR119 1138/4885NR3C1 37/4885CYP3A4 3719/4885 |
| US-12577231-B2 | Androgen receptor PROTACS | AR, CRBN, PSMA3 | GPR119 1138/4885NR3C1 37/4885CYP3A4 3719/4885 |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | CRBN, AR, GNRHR | GPR119 173/4885NR3C1 136/4885CYP3A4 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.